Results 201 to 210 of about 56,803 (285)

Cannabinoid Receptors in Myocardial Injury: A Brother Born to Rival. [PDF]

Int J Mol Sci, 2021
Tang X, Liu Z, Li X, Wang J, Li L.
europepmc   +1 more source

Exploring Linalool‐Based Phytotherapy for Excitatory/Inhibitory Imbalance in Alzheimer's Disease: A Review of Lavender and Cannabis Therapeutic Effects on Sleep, Seizures, and Cognition

Phytotherapy Research, Volume 40, Issue 5, Page 2604-2631, May 2026.
Schematic overview of the proposed neuromodulatory actions of linalool in Alzheimer's disease. Through multi‐target effects on oxidative stress, amyloid aggregation, GABAergic and glutamatergic signaling, linalool may restore excitatory/inhibitory balance.
Ilaria Piccialli, Giovanni Roviello, Giorgia Magliocca, Emilia Esposito, Anna Pannaccione   +4 more
wiley   +1 more source

Coordinated Regulation of CB1 Cannabinoid Receptors and Anandamide Metabolism Stabilizes Network Activity during Homeostatic Downscaling. [PDF]

eNeuro, 2022
Ye M, Monroe SK, Gay SM, Armstrong ML, Youngstrom DE, Urbina FL, Gupton SL, Reisdorph N, Diering GH.   +8 more
europepmc   +1 more source

Comparative Study on Burden, Features and Determinants of Disorders of Gut‐Brain Interaction Between Southern Europe and the Rest of Continent: Results From the Rome Foundation Global Epidemiology Study

United European Gastroenterology Journal, Volume 14, Issue 4, May 2026.
ABSTRACT Background and Aim Disorders of gut–brain interaction (DGBI) are highly prevalent worldwide. Although the epidemiology of DGBIs in Europe has been previously investigated, data comparing disease prevalence across European regions in relation to sociodemographic and lifestyle factors are lacking.
Giovanni Marasco, Keren Hod, Luigi Colecchia, Ami D. Sperber, Olafur S. Palsson, Shrikant I. Bangdiwala, Giovanni Barbara   +6 more
wiley   +1 more source

Gaining insights into MmpL3: combining structural and computational approaches to unlock transport and inhibitor‐binding mechanisms

Acta Crystallographica Section D, Volume 82, Issue 5, Page 550-570, May 2026.
This study investigates the mycobacterial membrane protein MmpL3, a key target for new antituberculosis drugs, by combining high‐resolution crystallography and computational simulations. It reveals how the inhibitor UPAR‐1109 binds to MmpL3, providing detailed insights into the function and flexibility of the protein and supporting the rational design ...
Satoshi Murakami, Domenico Marson, Eiki Yamashita, Bruno Broshka, Ui Okada, Maho Aoki, Giannamaria Annunziato, Erik Laurini, Emanuele Carosati, Marco Pieroni   +9 more
wiley   +1 more source

Comparative assessment of CacyBP/SIP, β-catenin and cannabinoid receptors in the adrenals of hypertensive rats. [PDF]

J Cell Mol Med
Smereczańska M, Domian N, Lewandowska A, Kasacka I.   +3 more
europepmc   +1 more source

Trends in toxicological findings and drug seizures of MDMA in New Zealand from 2010 to 2022

Journal of Forensic Sciences, Volume 71, Issue 3, Page 1338-1350, May 2026.
Abstract 3,4‐Methylenedioxymethamphetamine (MDMA) or “ecstasy,” is a commonly used drug worldwide, including in New Zealand, where 4.8% of the population aged 15 years or over reported using it in a 2023/2024 survey. This study provides additional insights on MDMA prevalence data in New Zealand by reporting toxicology data from Coronial and driving ...
Thomas J. Sheehan, Hilary J. Hamnett, Sarah G. G. Russell, Diana Kappatos, Helen Poulsen   +4 more
wiley   +1 more source

Microglial adenosine A_2A receptor in the paraventricular thalamic nucleus regulates pain sensation and analgesic effects independent of opioid and cannabinoid receptors. [PDF]

Front Pharmacol
Cao Y, Wu Z, Zhang M, Ji R, Zhang H, Song L.   +5 more
europepmc   +1 more source

Pharmacological and Mechanistic Interventions for Cognitive Impairment Associated With Schizophrenia: A Review of Registered Clinical Trials

Acta Psychiatrica Scandinavica, Volume 153, Issue 5, Page 402-431, May 2026.
ABSTRACT Background Schizophrenia is characterized by positive, negative, and cognitive symptoms. Current pharmacological treatments often fail to address cognitive deficits. In this review of clinical trials, we aim to identify studies that explore neurobiological (non‐psychological) strategies to address Cognitive Impairment Associated with ...
Bahareh Peyrovian, Lena Palaniyappan, Theodore T. Kolivakis, Howard C. Margolese   +3 more
wiley   +1 more source

Endocannabinoid system gene expression in mesocorticolimbic brain regions of individuals with alcohol use disorder: A descriptive study

Addiction, Volume 121, Issue 5, Page 1179-1189, May 2026.
Abstract Aims To describe differences in the expression of genes encoding cannabinoid receptors (CNR1, CNR2), the associated receptor GRP55 and the enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGLL) between individuals with alcohol use disorder (AUD) and controls in key mesocorticolimbic brain regions.
María Salud García‐Gutiérrez, Abraham Bailén Torregrosa, Francisco Navarrete, Auxiliadora Aracil‐Fernández, Gabriel Rubio, Jorge Manzanares   +5 more
wiley   +1 more source